产品详情
所在位置: 首页> 产品目录> 一抗>
查看大图

  • 产品名称：anti-CD19antibody(CD19Molecule)(PE)

  • 产品型号：
  • 产品厂商：Acris-antibodies
  • 产品文档：
你添加了1件商品 查看购物车
简单介绍：
anti-CD19antibody(CD19Molecule)(PE)
详情介绍：
Clone 1G9
Isotype IgG1
Specificity This antibody detects human B Lymphocytes. Identification of human B cells associated approximately with 10 % of peripheral blood lymphocytes, 95,000 M.W. surface antigen.
Characteristics Synonyms: Leu-12, B-cell marker, Differentiation antigen CD19, B-lymphocyte surface antigen B4
Alternative Name CD19 (CD19 Antibody Abstract)
Background CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 Molecule is expressed on 100 % of the peripheral B cells as defined by expression of kappa or lamda light chains. It is expressed on approximately 10 % of normal human peripheral blood cells and approximately 60 % of splenic lymphocytes. It is not expressed on granulocytes, monocytes or T cells as defined by CD3 expression. CD19 defines a pan B antigen which is expressed from the earliest stages of B progenitor development, but is lost on terminal differentiation to plasma cells. It may also be present on some early myeloid progenitors, particularly those of the monoblastic type. The CD19 antigen is expressed on approximately 12 % of peripheral blood lymphocytes. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen.Synonyms: B-cell marker, B-lymphocyte surface antigen B4, Differentiation antigen CD19, Leu-12
Gene ID 930
UniProt P15391
Research Area Stem Cells, Hematopoietic Progenitors, Hematopoietic Stem Cells, Adaptive Immunity, CD Antigens, Surface Receptors of Immune Cells
Pathways Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway
Application Notes Flow Cytometry. Monitoring of B cells in peripheral blood. Analysis of B cell subsets. Study of B cell activation. Study of B cell neoplasms.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Protocol PBMC: Add 10 ul of MAB/10e6 PBMC in 100 ul PBS. Mix gently and incubate for 15 minutes at 2-8°C. Wash twice with PBS and analyze or fix with 0. 5% v/v of paraformaldehyde in PBS andanalyze. WHOLE BLOOD: Add 10 ul of MAB/100 ul of whole blood. Mix gently and incubate for 15 minutes at room temperature (20°C). Lyse the whole blood. Wash once with PBS and analyze or fix with 0. 5% v/vof paraformaldehyde in PBS and analyze. See instrument manufacturers instructions for Lysed Whole Blood andImmunofluorescence analysis with a flow cytometer or microscope.
Restrictions For Research Use only
Buffer PBS containing 0.2 % protein carrier and 0.08 % Sodium Azide as preservative.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store the antibody undiluted at 2-8 °C. Do Not Freeze!
Shelf life: One year from despatch.
Expiry Date 12 months
Supplier Images
Flow Cytometry (FACS) image for anti-CD19 antibody (CD19 Molecule) (PE) (ABIN264227) anti-CD19 Molecule (CD19) antibody (PE)
Background publications Matsumoto, Kopicky-Burd, Carter, Tuveson, Tedder, Fearon: "Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19." in: The Journal of experimental medicine, Vol. 173, Issue 1, pp. 55-64, 1991 (PubMed).

Funderud, Erikstein, Asheim, Nustad, Stokke, Blomhoff, Holte, Smeland: "Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation." in: European journal of immunology, Vol. 20, Issue 1, pp. 201-6, 1990 (PubMed).

Leprince, Cohen-Kaminsky, Berrih-Aknin, Vernet-Der Garabedian, Treton, Galanaud, Richard: "Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 145, Issue 7, pp. 2115-22, 1990 (PubMed).

Borowitz, Shuster, Civin, Carroll, Look, Behm, Land, Pullen, Crist: "Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group study." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 8, Issue 8, pp. 1389-98, 1990 (PubMed).

Sulak, Clare, Morale, Hansen, Montiel: "Biphenotypic acute leukemia in *****s." in: American journal of clinical pathology, Vol. 94, Issue 1, pp. 54-8, 1990 (PubMed).